TTI 109
Alternative Names: TTI-109Latest Information Update: 19 Feb 2023
At a glance
- Originator Tvardi Therapeutics
- Class Small molecules
- Mechanism of Action STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 27 Jan 2023 Preclinical trials in Unspecified in USA (PO) (Tvardi Therapeutics pipeline, January 2023)